# Intranasal Recombinant Flagellin Subunit Campylobacter Vaccine (rFla-MBP) Dose-Ranging Study

> **NCT00124865** · PHASE1 · WITHDRAWN · sponsor: **U.S. Army Medical Research and Development Command**

## Conditions studied

- Diarrhea

## Interventions

- **BIOLOGICAL:** rFla-MBP

## Key facts

- **NCT ID:** NCT00124865
- **Lead sponsor:** U.S. Army Medical Research and Development Command
- **Sponsor class:** FED
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2005-07
- **Primary completion:** 2006-11
- **Final completion:** 2006-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor
- **Last updated:** 2017-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00124865

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00124865, "Intranasal Recombinant Flagellin Subunit Campylobacter Vaccine (rFla-MBP) Dose-Ranging Study". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00124865. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*